Chicago, IL—The surprising results of the head-to-head randomized clinical trial PISCES on patient preference for one cancer therapy over another show that patient-reported quality-of-life (QOL) differences influence treatment preference far more than physicians had imagined, suggested researchers at ASCO 2012.
Chicago, IL—Tivozanib, a potent investigational tyrosine kinase inhibitor with a long half-life, demonstrated significant improvement in progression-free survival (PFS) as first-line targeted therapy for metastatic renal-cell carcinoma (mRCC), according to results from a phase 3 randomized, open-label trial.
The results suggest that “tivozanib should be considered a first-line treatment option for metastatic RCC,” said Robert Motzer, MD, an oncologist at Memorial Sloan-Kettering Cancer Center, New York, and the trial’s lead investigator.
Chicago, IL—Upward dose titration of axitinib in patients who tolerate the starting dose may optimize drug exposure and improve the efficacy of the drug as a first-line therapy for metastatic renal-cell carcinoma (mRCC), said Brian I. Rini, MD, Associate Professor of Medicine at the Cleveland Clinic, at ASCO 2012.
Axitinib is a potent, selective, second-generation inhibitor of vascular endothelial growth factor receptors with demonstrated efficacy as second-line treatment for mRCC.
Chicago, IL—The list of choices for first-line pharmacologic therapy of metastatic renal-cell carcinoma (mRCC) is ever increasing. There are now 7 approved targeted therapies against the vascular endothelial growth factor (VEGF) and mammalian target of rapamycin (mTOR) pathways, said Daniel Y.C. Heng, MD, MPH, Clinical Associate Professor, Tom Baker Cancer Center, University of Calgary, Alberta, Canada, at ASCO 2012.
Results 1 - 4 of 4